Simulations Plus Overview

  • Status
  • Public
  • Employees
  • 111
Employees
  • Stock Symbol
  • SLP
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $67.14
  • (As of Thursday Closing)

Simulations Plus General Information

Description

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer that includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures; MedChem Studio which is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules among others.

Contact Information

Website
www.simulations-plus.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other IT Services
Stock Exchange
NAS
Primary Office
  • 42505 Tenth Street West
  • Lancaster, CA 93534
  • United States
+1 (661) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Simulations Plus Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$67.14 $66.11 $26.00 - $70.28 $1.2B 17.8M 259K $0.52

Simulations Plus Financials Summary

In Thousands,
USD 		TTM 31-May-2020 FY 2019 31-Aug-2019 FY 2018 31-Aug-2018 FY 2017 31-Aug-2017
EV 888,693 622,754 354,839 241,809
Revenue 40,075 33,970 29,667 24,138
EBITDA 14,108 13,382 12,986 10,398
Net Income 9,203 8,583 8,935 5,788
Total Assets 61,579 45,197 43,279 38,512
Total Debt 1,015 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Simulations Plus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Simulations Plus‘s full profile, request access.

Request a free trial

Simulations Plus Executive Team (5)

Name Title Board Seat Contact Info
Shawn O'Connor Chief Executive Officer
John Kneisel Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
To view Simulations Plus’s complete executive team members history, request access »

Simulations Plus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Simulations Plus Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 01-Apr-2020 000000000000000000 000.00 Drug Discovery 00000 0'000000
0000000 00000000 01-Jun-2017 000000000000000000 0000 Decision/Risk Analysis 0000 0000000
Cognigen Corporation 02-Sep-2014 Merger/Acquisition 000 Other Pharmaceuticals and Biotechnology 0000 0000000
To view Simulations Plus’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Simulations Plus Subsidiaries (3)

Company Name Industry Location Founded
DILIsym Services Decision/Risk Analysis NC 2011
00000000 000000000 Other Pharmaceuticals and Biotechnology Buffalo, NY 0000
000000 Drug Discovery Antony, France
To view Simulations Plus’s complete subsidiaries history, request access »